Cellectar Biosciences Tag

Cellectar Biosciences has been awarded a $2 million Phase II National Institutes of Health (NIH) SBIR grant from the National Cancer Institute (NCI), the company announced recently. According to a release, the grant will support a pivotal study of iopofosine I-131 in Waldenstrom’s Macroglobulinemia. “We appreciate the recognition...

Madison-based Cellectar Biosciences and LegoChemBio, a biotechnology company in South Korea, have entered a partnership aimed at developing and commercializing cancer therapies. According to a joint release, the companies will be able to develop new therapeutic drugs using Cellectar's drug-targeting platform in conjunction with LegoChemBio's...